Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by Ritonavir

Cancer Research

Volumn 62, Issue 21, 2002, Pages 6158-6164

  Bardelmeijer, Heleen A ^a   Ouwehand, Mariët ^a   Buckle, Tessa ^a   Huisman, Maarten T ^a   Schellens, Jan H M ^a,c   Beijnen, Jos H ^a,b,c   Van Tellingen, Olaf ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; DOCETAXEL; DRUG METABOLITE; GLYCOPROTEIN P; PACLITAXEL; PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG METABOLISM; FEMALE; FIRST PASS EFFECT; GASTROINTESTINAL ABSORPTION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PACLITAXEL; RITONAVIR; TAXOIDS;

EID: 0036829187     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Wacher, V. J., Salphati, L., and Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Delivery. Rev., 46: 89-102, 2001.
2. Juliano, R. L., and Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta, 455: 152-162, 1976.
3. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., and van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA, 94: 2031-2035, 1997.
4. van Asperen, J., van Tellingen, O., van der Valk, M. A., Rozenhart, M., and Beijnen, J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice with cyclosporin A. Clin. Cancer Res., 4: 2293-2297, 1998.
5. van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., and Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer, 76: 1181-1183, 1997.
6. Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H., and van Tellingen, O. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res., 6: 4416-4421, 2000.
7. Meerum Terwogt, J. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., and Schellens, J. H. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet, 352: 285, 1998.
8. Meerum Terwogt, J. M., Malingre, M. M., Beijnen, J. H., ten Bokkel Huinink, W. W., Rosing, H., Koopman, F. J., van Tellingen, O., Swart, M., and Schellens, J. H. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res., 5: 3379-3384, 1999.
9. Huizing, M. T., Misser, V. H., Pieters, R. C., ten Bokkel Huinink, W. W., Veenhof, C. H., Vermorken, J. B., Pinedo, H. M., and Beijnen, J. H. Taxanes: A new class of antitumor agents. Cancer Investig., 13: 381-404. 1995.
10. Ringel, I., and Horwitz, S. B. Studies with RP 56976 (Taxotere): A semisynthetic analogue of Taxol. J. Natl. Cancer Inst. (Bethesda), 83: 288-291, 1991.
11. Monegier, B., Gaillard, C., Sable, S., and Vuilhorgne, M. Structures of the major metabolites of docetaxel (RP 56976-Taxotere). Tetrahedron Lett., 35: 3715-3718, 1994.
12. Sparreboom, A., van Tellingen, O., Nooijen, W. J., and Beijnen, J. H. Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semiautomated reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Appl., 664: 383-391, 1995.
13. Wils, P., Phung-Ba, V., Warnery, A., Lechardeur, D., Raeissi, S. D., Hidalgo, I. J., and Scherman, D. Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem. Pharmacol., 48: 1528-1530, 1994.
14. Shirakawa, K., Takara, K., Tanigawara, Y., Aoyama, N., Kasuga, M., Komada, F., Sakaeda, T., and Okumura, K. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn. J. Cancer Res., 90: 1380-1386, 1999.
15. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A. A. M., van Deemter, L., Smit, J. J. M., van der Valk, M. A., Voordouw, A. C., Spits, H., van Telingen, O., Zijlmans, J. M., Fibbe, W. E., and Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. USA, 94: 4028-4033, 1997.
16. Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., and Borst, P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Investig., 96: 1698-1705, 1995.
17. Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J., and Wrighton, S. A. Selectivity of the multidrug resistance modulator. LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther., 290: 854-862, 1999.
18. van Tellingen, O., Beijnen, J. H., Verweij, J., Scherrenburg, E. J., Nooijen, W. J., and Sparreboom, A. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin. Cancer Res., 5: 2918-2924, 1999.
19. Yanagimoto, T., Itoh, S., Sawada, M., and Kamataki, T. Mouse cytochrome P450 (Cyp3a1 1): Predominant expression in liver and capacity to activate aflatoxin B1. Arch. Biochem. Biophys., 340: 215-218, 1997.
20. Yanagimoto, T., Itoh, S., Sawada, M., Hashimoto, H., and Kamataki, T. Molecular cloning and functional expression of a mouse cytochrome P-450 (Cyp3a-13): Examination of Cyp3a-13 enzyme to activate aflatoxin B1 (AFB1). Biochim. Biophys. Acta, 1201: 405-410, 1994.
21. Marre, F., Sanderink, G, J., Desousa, G., Galliard, C., Martinet, M., and Rahmani, R. Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res, 56: 1296-1302, 1996.
22. Alsenz, J., Steffen, H., and Alex, R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm. Res. (NY), 15: 423-428, 1998.
23. Drewe, J., Gutmann, H., Fricker, G., Torok, M., Beglinger, C., and Huwyler, J. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem. Pharmacol., 57: 1147-1152, 1999.
24. Profit, L., Eagling, V. A., and Back, D. J. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS (Hagerstown), 13: 1623-1627, 1999.
25. Gutmann, H., Fricker, G., Drewe, J., Toeroek, M., and Miller, D. S. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol. Pharmacol., 56: 383-389, 1999.
26. Lee, C. G., Gottesman, M. M., Cardarelli, C. O., Ramachandra, M., Jeang, K. T., Ambudkar, S. V., Pastan, I., and Dey, S. HIV-1 protease inhibitors are substrates for the MDRI multidrug transporter. Biochemistry, 37: 3594-3601, 1998.
27. Wacher, V. J., Wu, C. Y., and Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 13: 129-134, 1995.
28. Watkins, P. B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Delivery Rev., 27: 161-170, 1997.
29. Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., and Wacher, V. J. Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J. Controlled Release, 62: 25-31, 1999.
30. Kim, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., Wood, A. J. J., and Wilkinson, G. R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. (NY), 16: 408-414, 1999.
31. Zhang, Y., and Benet, L. Z. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinetics, 40: 159-168, 2001.
32. Malingré, M. M., Richel, D. J., Beijnen, J. H., Rosing, H., Koopman, F. J., Bokkel Huinink, W. W., Schot, M. E., and Schellens, J. H. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J. Clin. Oncol., 19: 1160-1166, 2001.
33. Wacher, V. J., Silverman, J. A., Zhang, Y., and Benet, L. Z. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci., 87: 1322-1330, 1998.
34. Veldkamp, A. I., van Heeswijk, R. P., Mulder, J. W., Meenhorst, P. L., Schreij, G., van der Geest, S., Lange, J. M., Beijnen, J. H., and Hoetelmans, R. M. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes, 27: 344-349, 2001.
35. van Heeswijk, R. P., Veldkamp, A. I., Hoetelmans, R. M., Mulder, J. W., Schreij, G., Hsu, A., Lange, J. M., Beijnen, J. H., and Meenhorst, P. L. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS (Hagerstown), 13: F95-F99, 1999.